Volume 33 Issue 3
May  2012
Turn off MathJax
Article Contents

ZHU Hui-Fang, ZHANG Yuan-Xu, ZHAO Xu-Dong. Animal models of human glioma: the progress of application and investigation. Zoological Research, 2012, 33(3): 337-342. doi: 10.3724/SP.J.1141.2012.03337
Citation: ZHU Hui-Fang, ZHANG Yuan-Xu, ZHAO Xu-Dong. Animal models of human glioma: the progress of application and investigation. Zoological Research, 2012, 33(3): 337-342. doi: 10.3724/SP.J.1141.2012.03337

Animal models of human glioma: the progress of application and investigation

doi: 10.3724/SP.J.1141.2012.03337
  • Received Date: 2012-01-09
  • Rev Recd Date: 2012-02-07
  • Publish Date: 2012-06-22
  • The glioma accounts for half of the central nervous tumors, among which the glioblastoma multiforme (GBM) is one of the most aggressive and lethal brain tumors. The difficulties in glioma therapy indicate the need of appropriate animal models for preclinical studies. Benefiting from the development of molecular biology, genetics, and transgenic technology, variable animal models of glioma have been established. These animal models of human glioma are reviewed in this paper.
  • 加载中
  • [1] A hmed AU, Thaci B, Alexiades NG, Han Y, Qian S, Liu FF, Balyasnikova IV, Ulasov IY, Aboody KS, Lesniak MS. 2011. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma[J]. Mol Ther, 19(9): 1714-1726.
    [2] Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD. 2004. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance[J]. J Neuropathol Exp Neurol, 63(7): 700-707.
    [3] Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, Tang Y, DeFrances J, Stover E, Weissleder R, Rowitch DH, Louis DN, DePinho RA. 2002. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis[J]. Cancer Cell, 1(3): 269-277.
    [4] Bao SD, Wu QL, McLendon RE, Hao YL, Shi Q, Hjelmeland AB, DewhirstMW, Bigner DD, Rich JN. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response[J]. Nature, 444(7120): 756-760.
    [5] Bleau AM, Howard BM, Taylor LA, Gursel D, Greenfield JP, Lim Tung HY,Holland EC, Boockvar JA. 2008. New strategy for the analysis of phenotypic marker antigens in brain tumor-derived neurospheres in mice and humans[J]. Neurosurg Focus, 24(3-4): E28.
    [6] Branle F, Lefranc F, Camby I, Jeuken J, Geurts-Moespot A, Sprenger S, Sweep F, Kiss R, Salmon I. 2002. Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy[J]. Cancer, 95(3): 641-655.
    [7] Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE,McNiel EA, Ohlfest JR, Freese AB, Moore PF, Lerner J, Lowenstein PR, Castro MG. 2007. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression[J]. J Neurooncol, 85(2): 133-148.
    [8] Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways[J]. Nature, 455(7216): 1061-1068.
    [9] Chen J, Kwon CH, Lin L, Li YJ, Parada LF. 2009. Inducible site-specific recombination in neural stem/progenitor cells[J]. Genesis, 47(2): 122-131.
    [10] Copeland DD, Talley FA, Bigner DD. 1976. The fine structure of intracranial neoplasms induced by the inoculation of avian sarcoma virus in neonatal and adult rats[J]. Am J Pathol, 83(1): 149-176.
    [11] de Vries NA, Beijnen JH, van Tellingen O. 2009. High-grade glioma mouse models and their applicability for preclinical testing[J]. Cancer Treat Rev, 35(8): 714-123.
    [12] de Vries NA, Bruggeman SW, Hulsman D, de Vries HI, Zevenhoven J, Buckle T, Hamans BC, Leenders WP, Beijnen JH, van Lohuizen M,Berns AJM, van Tellingen O. 2010. Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies[J].Clin Cancer Res, 16(13): 3431-3441.
    [13] Ding H, Shannon P, Lau N, Wu XL, Roncari L, Baldwin RL, Takebayashi H,Nagy A, Gutmann DH, Guha A. 2003. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model[J]. Cancer Res, 63(5): 1106-1113.
    [14] Du W, Chen MQ, Wu ZP. 2005. The research progress of mice tumor model[J]. Chn J Pract Med, 4(11): 1120-1122. [杜伟, 陈明清, 吴治平. 2005. 建立小鼠肿瘤模型的研究进展[J]. 中华医学实践杂志, 4(11): 1120-1122.]
    [15] Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. 2007. Malignant astrocytic glioma: genetics, biology, and paths to treatment[J]. Genes Dev, 21(21): 2683-2710.
    [16] Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R,Foroni C, Dimeco F, Vescovi A. 2004. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma[J].Cancer Res, 64(19): 7011-7021.
    [17] Ghods AJ, Irvin D, Liu GT, Yuan XP, Abdulkadir IR, Tunici P, Konda B,Wachsmann-Hogiu S, Black KL, Yu JS. 2007. Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells[J]. Stem Cells, 25(7): 1645-1653.
    [18] Holland EC, Celestino J, Dai CK, Schaefer L, Sawaya RE, Fuller GN. 2000.Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice[J]. Nat Genet, 25(1): 55-57.
    [19] Jacques TS, Swales A, Brzozowski MJ, Henriquez NV, Linehan JM,Mirzadeh Z, O'Malley C, Naumann H, Alvarez-Buylla A, Brandner S. 2010. Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes[J]. EMBO J, 29(1): 222-235.
    [20] Kish PE, Blaivas M, Strawderman M, Muraszko KM, Ross DA, Ross BD,McMahon G. 2001. Magnetic resonance imaging of ethyl-nitrosourea-induced rat gliomas: a model for experimental therapeutics of low-grade gliomas[J]. J Neurooncol, 53(3): 243-257.
    [21] Koestner A. 1990. Characterization of N-nitrosourea-induced tumors of the nervous system; their prospective value for studies of neurocarcinogenesis and brain tumor therapy[J]. Toxicol Pathol, 18(2): 186-192.
    [22] Kondo T, Setoguchi T, Taga T. 2004. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line[J]. Proc Natl Acad Sci USA, 101(3): 781-786.
    [23] Krynska B, Otte J, Franks R, Khalili K, Croul S. 1999. Human ubiquitous JCV(CY) T-antigen gene induces brain tumors in experimental animals[J]. Oncogene, 18(1): 39-46.
    [24] Kwon CH, Zhao DW, Chen J, Alcantara S, Li YJ, Burns DK, Mason RP,Lee EYHP, Wu H, Parada LF. 2008. Pten haploinsufficiency accelerates formation of high-grade astrocytomas[J]. Cancer Res, 68(9): 3286-3294.
    [25] Lee J, Kotliarova S, Kotliarov Y, Li AG, Su Q, Donin NM, Pastorino S,Purow BW, Christopher N, Zhang W, Park JK, Fine HA. 2006. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines[J]. Cancer Cell, 9(5): 391-403.
    [26] Li L, Dutra A, Pak E, Labrie JE III, Gerstein RM, Pandolfi PP, Recht LD,Ross AH. 2009. EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors[J]. Neuro Oncol, 11(1): 9-21.
    [27] Llaguno SA, Chen J, Kwon CH, Jackson EL, Li YJ, Burns DK,Alvarez-Buylla A, Parada LF. 2009. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model[J]. Cancer Cell, 15(1): 45-56.
    [28] London WT, Houff SA, Madden DL, Fuccillo DA, Gravell M, Wallen WC,Palmer AE, Sever JL, Padgett BL, Walker DL, ZuRhein GM, Ohashi T. 1978. Brain tumors in owl monkeys inoculated with a human polyomavirus (JC virus)[J]. Science, 201(4362): 1246-1249.
    [29] Maes W, Van Gool SW. 2011. Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model[J]. Cancer Immunol Immunother, 60(2): 153-160.
    [30] Marumoto T, Tashiro A, Friedmann-Morvinski D, Scadeng M, Soda Y, Gage FH, Verma IM. 2009. Development of a novel mouse glioma model using lentiviral vectors[J]. Nat Med, 15(1): 110-116.
    [31] Parsa AT, Chakrabarti I, Hurley PT, Chi JH, Hall JS, Kaiser MG, Bruce JN. 2000. Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy[J]. Neurosurgery, 47(4): 993-1000.
    [32] Pellegatta S, Poliani PL, Corno D, Menghi F, Ghielmetti F, Suarez-Merino B, Caldera V, Nava S, Ravanini M, Facchetti F, Bruzzone MG,Finocchiaro G. 2006. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas[J]. Cancer Res, 66(21): 10247-10252.
    [33] Radaelli E, Ceruti R, Patton V, Russo M, Degrassi A, Croci V, Caprera F,Stortini G, Scanziani E, Pesenti E, Alzani R. 2009.Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease[J]. Histol Histopathol, 24(7): 879-891.
    [34] Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. 2000.Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects[J]. Nat Genet, 26(1): 109-113.
    [35] Stojiljkovic M, Piperski V, Dacevic M, Rakic L, Ruzdijic S, Kanazir S. 2003.Characterization of 9L glioma model of the Wistar rat[J]. J Neurooncol, 63(1): 1-7.
    [36] Sughrue ME, Yang I, Kane AJ, Rutkowski MJ, Fang SN, James CD, Parsa AT. 2009. Immunological considerations of modern animal models of malignant primary brain tumors[J]. J Transl Med, 7(1): 84.
    [37] Tabuchi K, Nishimoto A, Matsumoto K, Satoh T, Nakasone S, Fujiwara T,Ogura H. 1985. Establishment of a brain-tumor model in adult monkeys[J]. J Neurosurg, 63(6): 912-916.
    [38] Uhrbom L, Holland EC. 2001. Modeling gliomagenesis with somatic cell gene transfer using retroviral vectors[J]. J Neurooncol, 53(3): 297-305.
    [39] Watanabe T, Yokoo H, Yokoo M, Yonekawa Y, Kleihues P, Ohgaki H. 2001.Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas[J]. J Neuropathol Exp Neurol, 60(12): 1181-1189.
    [40] Wei QX, Clarke L, Scheidenhelm DK, Qian BP, Tong A, Sabha N, Karim Z,Bock NA, Reti R, Swoboda R, Purev E, Lavoie JF, Bajenaru ML,Shannon P, Herlyn D, Kaplan D, Henkelman RM, Gutmann DH, Guha A. 2006. High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model[J]. Cancer Res, 66(15): 7429-7437.
    [41] Weiss WA, Burns MJ, Hackett C, Aldape K, Hill JR, Kuriyama H,Kuriyama N, Milshteyn N, Roberts T, Wendland MF, DePinho R, Israel MA. 2003. Genetic determinants of malignancy in a mouse model for oligodendroglioma[J]. Cancer Res, 63(7): 1589-1595.
    [42] Yuan XP, Curtin J, Xiong YZ, Liu GT, Waschsmann-Hogiu S, Farkas DL,Black KL, Yu JS. 2004. Isolation of cancer stem cells from adult glioblastoma multiforme[J]. Oncogene, 23(58): 9392-9400.
    [43] Zhu HH, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, Pfannl R, Bronson RT, Chen JW, Weissleder R, Housman DE, Charest A. 2009.
    [44] Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis[J]. Proc Natl Acad Sci USA, 106(8): 2712-2716.
    [45] Zhu Y, Guignard F, Zhao DW, Liu L, Burns DK, Mason RP, Messing A,Parada LF. 2005. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma[J]. Cancer Cell, 8(2): 119-130.
    [46] Zhu Y, Parada LF. 2002. The molecular and genetic basis of neurological tumours[J]. Nat Rev Cancer, 2(8): 616-626.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(2759) PDF downloads(2519) Cited by()

Related
Proportional views

Animal models of human glioma: the progress of application and investigation

doi: 10.3724/SP.J.1141.2012.03337

Abstract: The glioma accounts for half of the central nervous tumors, among which the glioblastoma multiforme (GBM) is one of the most aggressive and lethal brain tumors. The difficulties in glioma therapy indicate the need of appropriate animal models for preclinical studies. Benefiting from the development of molecular biology, genetics, and transgenic technology, variable animal models of glioma have been established. These animal models of human glioma are reviewed in this paper.

ZHU Hui-Fang, ZHANG Yuan-Xu, ZHAO Xu-Dong. Animal models of human glioma: the progress of application and investigation. Zoological Research, 2012, 33(3): 337-342. doi: 10.3724/SP.J.1141.2012.03337
Citation: ZHU Hui-Fang, ZHANG Yuan-Xu, ZHAO Xu-Dong. Animal models of human glioma: the progress of application and investigation. Zoological Research, 2012, 33(3): 337-342. doi: 10.3724/SP.J.1141.2012.03337
Reference (46)

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return